7 IPOs Expected This Week

|
 |  Includes: AMBO, DMEDF, GMAN, IL, MRK, NXPI, SRGV, TEVA
by: Renaissance Capital IPO Research

The following 7 IPOs are expected to price this week:

Ambow Education Holding (NYSE:AMBO), which provides education, test prep and IT career training services in China, plans to raise $117 million by offering 10,677,210 at a price range of $10.00 to $12.00. At the mid-point of the proposed range, Ambow Education Holding will command a market value of $844.24 million. Ambow Education Holding, which was founded in 2000, booked $146 million in sales over the last 12 months. The Beijing, China-based company plans to list on the NYSE under the symbol AMBO. J.P. Morgan (NYSE:JPM), Goldman Sachs (Asia) L.L.C. (NYSE:GS) are the lead underwriters on the deal.

D. Medical (DMED), a medical device company that develops and manufactures insulin pumps, plans to raise $30 million by offering 2,727,273 at a price range of $10.00 to $12.00. At the mid-point of the proposed range, D. Medical will command a market value of $98.33 million. D. Medical, which was founded in 1992, booked $0 million in sales over the last 12 months. The Ramat Gan, Israel-based company plans to list on the NASDAQ under the symbol DMED. Rodman & Renshaw (NYSEARCA:RODM), ThinkEquity are the lead underwriters on the deal.

Gordmans Stores (NASDAQ:GMAN), an everyday low price fashion retailer operating 68 stores in the Midwest, plans to raise $75 million by offering 5,357,143 at a price range of $13.00 to $15.00. At the mid-point of the proposed range, Gordmans Stores will command a market value of $261.84 million. Gordmans Stores, which was founded in 1915, booked $458 million in sales over the last 12 months. The Omaha, NE-based company plans to list on the NASDAQ under the symbol GMAN. Piper Jaffray (NYSE:PJC), Wells Fargo Securities (NYSE:WFC) are the lead underwriters on the deal.

IntraLinks Holdings (NYSE:IL), which provides secure online document management to over 4,300 customers, plans to raise $165 million by offering 11,000,000 at a price range of $14.00 to $16.00. At the mid-point of the proposed range, IntraLinks Holdings will command a market value of $766.70 million. IntraLinks Holdings, which was founded in 1996, booked $141 million in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol IL. Morgan Stanley (NYSE:MS), Deutsche Bank Securities (NYSE:DB), and Credit Suisse (NYSE:CS) are the lead underwriters on the deal.

NuPathe (PATH), a specialty pharma seeking approval for Zelrix, a patch for migraine treatment, plans to raise $75 million by offering 5,000,000 at a price range of $14.00 to $16.00. At the mid-point of the proposed range, NuPathe will command a market value of $211.68 million. NuPathe, which was founded in 2005, booked $0 million in sales over the last 12 months. The Conshohocken, PA-based company plans to list on the NASDAQ under the symbol PATH. Leerink Swann, Lazard Capital Markets (NYSE:LAZ) are the lead underwriters on the deal.

NXP Semiconductors (NASDAQ:NXPI), a diversified global semiconductor company and former carve-out of Philips, plans to raise $663 million by offering 34,000,000 at a price range of $18.00 to $21.00. At the mid-point of the proposed range, NXP Semiconductors will command a market value of $4,860.40 million. NXP Semiconductors, which was founded in 1953, booked $3,843 million in sales over the last 12 months. The Eindhoven, Netherlands-based company plans to list on the NASDAQ under the symbol NXPI. Credit Suisse, Goldman, Sachs & Co., and Morgan Stanley are the lead underwriters on the deal. Please note: *Filed with SEC under KASLION Acquisition B.V.

SurgiVision (SRGV), which has developed an MRI-guided device for minimally invasive brain procedures, plans to raise $25 million by offering 2,500,000 at a price range of $13.00 to $15.00. At the mid-point of the proposed range, SurgiVision will command a market value of $111.01 million. SurgiVision, which was founded in 1998, booked $3 million in sales over the last 12 months. The Memphis, TN-based company plans to list on the NASDAQ under the symbol SRGV. Canaccord Genuity (OTC:CCDPF), Rodman & Renshaw are the lead underwriters on the deal. Please note: *Lowered range to $9-$11 (was $13-$15) [Update: IPO is now postponed.]

Trius Therapeutics (TSRX), which is developing an antibiotic for serious gram-positive Staph infections, plans to raise $78 million by offering 6,000,000 at a price range of $12.00 to $14.00. At the mid-point of the proposed range, Trius Therapeutics will command a market value of $216.82 million. Trius Therapeutics, which was founded in 2004, booked $5 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol TSRX. Citi (NYSE:C), Piper Jaffray, and Canaccord Genuity are the lead underwriters on the deal. Please note: *Previously postponed on 3/1/2010 due to modification of its Ph. 3 trials, refiled amendment on 6/16/2010.

Last week, there were 3 IPO pricings. Envestnet (NYSE:ENV), which provides outsourced web-based investment solutions to financial advisors, was the week's winner, ending up 12% from its IPO price.